Hyperbaric Oxygen Treatment for Necrotizing Fasciitis and Necrotizing Soft Tissue Infections

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCorewell Health West

About this trial

The goal of this clinical trial is to learn if hyperbaric oxygen is beneficial in treating necrotizing infections and decreasing rates of morbidity and mortality. This study therefore has two aims:

1. Determine if hyperbaric oxygen improve morbidity and mortality compared to standard of care using a prospective model. 2. Determine if faster diagnosis to debridement times negate the need for hyperbaric oxygen treatments in necrotizing infections.

Eligibility criteria

Qualifiers

Age: 18 years old

Patients with documented necrotizing fasciitis or necrotizing soft tissue infection as assessed during initial bedside evaluation, in conjunction with available laboratory values, imaging showing gas in soft tissues consitent with necrotizing infection, or surgical debridement of necrosis of fascia, muscle, and variable levels of soft tissue involvement

Patient or advocate is able to sign consent

Disqualifiers

Pediatric patients

Pregnant patients

Patients deemed unlikely to survive or unable to go to surgical debridement

Trial design

Treatments tested in this trial

  • Hyperbaric Oxygen Therapy

Treatment groups

160 Participants
are divided into 2 treatment groups

Sponsors and collaborators